Open AccessImpact of lamivudine on HIV and hepatitis B virus-related outcomes in HIV/hepatitis B virus individuals in a randomized clinical trial of antiretroviral therapy in southern Africa
Author(s) -
Gail V. Matthews,
Prince Manzini,
Zonghui Hu,
Paul Khabo,
Patrick Maja,
Gugu Matchaba,
Phumele Sangweni,
Julie Metcalf,
Nicholaas Pool,
Susan Orsega,
Sean Emery
Publication year - 2011
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0b013e328349bbf3
Subject(s) - lamivudine , coinfection , medicine , stavudine , hepatitis b virus , hepatitis b , virology , immunology , didanosine , zidovudine , gastroenterology , virus , viral disease
To examine HIV and hepatitis B virus (HBV)-related outcomes in HIV/HBV-coinfected participants in the PHIDISA II study by use of HBV-active vs. non-HBV-active antiretroviral therapy (ART).